Comparison of Transplanted Kidney Function in Patients on Two Different Doses of Mycophenolate Mofetil

H. T. Khosroshahi, A. Nahali, M. Gojazadeh, Mohammadali Mohajel Shoja

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Mycophenolate mofetil (MMF), an immunosuppressant that is widely used in renal transplant recipients, is associated with several dose-dependent hematologic and gastrointestinal side effects that lead to drug dose reduction or even discontinuation. The aim of this study was to compare the renal function and acute rejection rates of kidney allograft recipients who were on two different mycophenolate mofetil doses. Methods: In a prospective study, 59 allograft kidney recipients who were on MMF 2 g/d were randomly selected and followed for evidences of acute rejection or drug side effects. Four patients were excluded from the study due to noncompliance, graft loss, and patient loss from opportunistic infection. Of the remaining 55 patients, 22 patients (40%) underwent MMF dose reduction to 1.35 ± 0.23 g/d due to perceived side effects or economic reasons (group 1). The mean time for this change was 4.2 ± 2.1 months after the kidney transplantation. The remaining patients (group 2, n = 33, 60%) had no change in MMF 2 g/d drug dosage. All patients were followed for at least 30 months after transplantation. Renal function tests (blood urea and serum cratinine) were measured monthly. Statistical analysis was performed using SPSS 11.0 (Student t test). A P value < .05 was considered significant. Results: The two groups were comparable regarding age, gender, other immunosuppressive medications, and the time after transplantation. There were no episodes of acute rejection in group 1 after MMF dose reduction. The renal function (blood urea or serum creatinine levels) was comparable between the two groups at the end of study (P = .846 and .610, respectively). Conclusion: MMF dose reduction was not associated with an increased risk of acute renal allograft rejection or impaired graft function.

Original languageEnglish (US)
Pages (from-to)2035-2037
Number of pages3
JournalTransplantation Proceedings
Volume38
Issue number7
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Mycophenolic Acid
Kidney
Allografts
Immunosuppressive Agents
Urea
Transplantation
Transplants
Opportunistic Infections
Drug-Related Side Effects and Adverse Reactions
Serum
Pharmaceutical Preparations
Kidney Transplantation
Creatinine
Economics
Prospective Studies
Students

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Comparison of Transplanted Kidney Function in Patients on Two Different Doses of Mycophenolate Mofetil. / Khosroshahi, H. T.; Nahali, A.; Gojazadeh, M.; Mohajel Shoja, Mohammadali.

In: Transplantation Proceedings, Vol. 38, No. 7, 01.09.2006, p. 2035-2037.

Research output: Contribution to journalArticle

Khosroshahi, H. T. ; Nahali, A. ; Gojazadeh, M. ; Mohajel Shoja, Mohammadali. / Comparison of Transplanted Kidney Function in Patients on Two Different Doses of Mycophenolate Mofetil. In: Transplantation Proceedings. 2006 ; Vol. 38, No. 7. pp. 2035-2037.
@article{99356790a9754f2f87049572d293c6d0,
title = "Comparison of Transplanted Kidney Function in Patients on Two Different Doses of Mycophenolate Mofetil",
abstract = "Introduction: Mycophenolate mofetil (MMF), an immunosuppressant that is widely used in renal transplant recipients, is associated with several dose-dependent hematologic and gastrointestinal side effects that lead to drug dose reduction or even discontinuation. The aim of this study was to compare the renal function and acute rejection rates of kidney allograft recipients who were on two different mycophenolate mofetil doses. Methods: In a prospective study, 59 allograft kidney recipients who were on MMF 2 g/d were randomly selected and followed for evidences of acute rejection or drug side effects. Four patients were excluded from the study due to noncompliance, graft loss, and patient loss from opportunistic infection. Of the remaining 55 patients, 22 patients (40{\%}) underwent MMF dose reduction to 1.35 ± 0.23 g/d due to perceived side effects or economic reasons (group 1). The mean time for this change was 4.2 ± 2.1 months after the kidney transplantation. The remaining patients (group 2, n = 33, 60{\%}) had no change in MMF 2 g/d drug dosage. All patients were followed for at least 30 months after transplantation. Renal function tests (blood urea and serum cratinine) were measured monthly. Statistical analysis was performed using SPSS 11.0 (Student t test). A P value < .05 was considered significant. Results: The two groups were comparable regarding age, gender, other immunosuppressive medications, and the time after transplantation. There were no episodes of acute rejection in group 1 after MMF dose reduction. The renal function (blood urea or serum creatinine levels) was comparable between the two groups at the end of study (P = .846 and .610, respectively). Conclusion: MMF dose reduction was not associated with an increased risk of acute renal allograft rejection or impaired graft function.",
author = "Khosroshahi, {H. T.} and A. Nahali and M. Gojazadeh and {Mohajel Shoja}, Mohammadali",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.transproceed.2006.06.040",
language = "English (US)",
volume = "38",
pages = "2035--2037",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Comparison of Transplanted Kidney Function in Patients on Two Different Doses of Mycophenolate Mofetil

AU - Khosroshahi, H. T.

AU - Nahali, A.

AU - Gojazadeh, M.

AU - Mohajel Shoja, Mohammadali

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Introduction: Mycophenolate mofetil (MMF), an immunosuppressant that is widely used in renal transplant recipients, is associated with several dose-dependent hematologic and gastrointestinal side effects that lead to drug dose reduction or even discontinuation. The aim of this study was to compare the renal function and acute rejection rates of kidney allograft recipients who were on two different mycophenolate mofetil doses. Methods: In a prospective study, 59 allograft kidney recipients who were on MMF 2 g/d were randomly selected and followed for evidences of acute rejection or drug side effects. Four patients were excluded from the study due to noncompliance, graft loss, and patient loss from opportunistic infection. Of the remaining 55 patients, 22 patients (40%) underwent MMF dose reduction to 1.35 ± 0.23 g/d due to perceived side effects or economic reasons (group 1). The mean time for this change was 4.2 ± 2.1 months after the kidney transplantation. The remaining patients (group 2, n = 33, 60%) had no change in MMF 2 g/d drug dosage. All patients were followed for at least 30 months after transplantation. Renal function tests (blood urea and serum cratinine) were measured monthly. Statistical analysis was performed using SPSS 11.0 (Student t test). A P value < .05 was considered significant. Results: The two groups were comparable regarding age, gender, other immunosuppressive medications, and the time after transplantation. There were no episodes of acute rejection in group 1 after MMF dose reduction. The renal function (blood urea or serum creatinine levels) was comparable between the two groups at the end of study (P = .846 and .610, respectively). Conclusion: MMF dose reduction was not associated with an increased risk of acute renal allograft rejection or impaired graft function.

AB - Introduction: Mycophenolate mofetil (MMF), an immunosuppressant that is widely used in renal transplant recipients, is associated with several dose-dependent hematologic and gastrointestinal side effects that lead to drug dose reduction or even discontinuation. The aim of this study was to compare the renal function and acute rejection rates of kidney allograft recipients who were on two different mycophenolate mofetil doses. Methods: In a prospective study, 59 allograft kidney recipients who were on MMF 2 g/d were randomly selected and followed for evidences of acute rejection or drug side effects. Four patients were excluded from the study due to noncompliance, graft loss, and patient loss from opportunistic infection. Of the remaining 55 patients, 22 patients (40%) underwent MMF dose reduction to 1.35 ± 0.23 g/d due to perceived side effects or economic reasons (group 1). The mean time for this change was 4.2 ± 2.1 months after the kidney transplantation. The remaining patients (group 2, n = 33, 60%) had no change in MMF 2 g/d drug dosage. All patients were followed for at least 30 months after transplantation. Renal function tests (blood urea and serum cratinine) were measured monthly. Statistical analysis was performed using SPSS 11.0 (Student t test). A P value < .05 was considered significant. Results: The two groups were comparable regarding age, gender, other immunosuppressive medications, and the time after transplantation. There were no episodes of acute rejection in group 1 after MMF dose reduction. The renal function (blood urea or serum creatinine levels) was comparable between the two groups at the end of study (P = .846 and .610, respectively). Conclusion: MMF dose reduction was not associated with an increased risk of acute renal allograft rejection or impaired graft function.

UR - http://www.scopus.com/inward/record.url?scp=33846113324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846113324&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.06.040

DO - 10.1016/j.transproceed.2006.06.040

M3 - Article

VL - 38

SP - 2035

EP - 2037

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 7

ER -